secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ceribell, Inc. (CBLL)
CIK:        0001861107
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001193125-25-312035
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ceribell receives FDA 510(k) clearance for first delirium monitoring solution
-----------------------------------------------------------------------------

- FDA cleared Ceribell's EEG-based delirium screening and monitoring system for critically ill patients.
- Algorithm validated in prospective study of 225 adults in critical care; continuous monitoring at bedside.
- Delirium affects ~31% of ICU patients and up to 80% of mechanically ventilated; associated with higher mortality and dementia risk.
- Ceribell has submitted NTAP application to CMS for the new indication; leverages existing commercial footprint.
- CEO Jane Chao expects to finalize go-to-market strategy soon; builds on prior Breakthrough Device Designation (2022).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861107/000119312525312035/0001193125-25-312035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861107/000119312525312035/cbll-20251209.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-312035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer